The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 29, 2020

Filed:

Dec. 01, 2016
Applicants:

The Procter & Gamble Company, Cincinnati, OH (US);

The Cleveland Clinic Foundation, Cleveland, OH (US);

Inventors:

Stanley Leon Hazen, Pepper Pike, OH (US);

Jose Carlos Garcia-Garcia, Cincinnati, OH (US);

George Franklin Gerberick, Cincinnati, OH (US);

John August Wos, Mason, OH (US);

David Thomas Stanton, Hamilton, OH (US);

Thomas Alfred Inglin, Loveland, OH (US);

Michael Reilly, Lebanon, OH (US);

Angela Jane Deutsch, West Chester, OH (US);

Jodie Michele Reed, Loveland, OH (US);

David Blair Cody, West Harrison, IN (US);

Assignees:

The Procter & Gamble Company, Cincinnati, OH (US);

The Cleveland Clinic Foundation, Cleveland, OH (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/26 (2006.01); A61K 31/166 (2006.01); A61K 31/216 (2006.01); A61K 31/22 (2006.01); A61K 31/325 (2006.01); A61K 31/351 (2006.01); A61K 45/06 (2006.01); C07D 213/04 (2006.01); C07D 295/13 (2006.01);
U.S. Cl.
CPC ...
A61K 31/26 (2013.01); A61K 31/166 (2013.01); A61K 31/216 (2013.01); A61K 31/22 (2013.01); A61K 31/325 (2013.01); A61K 31/351 (2013.01); A61K 45/06 (2013.01); C07D 213/04 (2013.01); C07D 295/13 (2013.01);
Abstract

The invention provides a method of inhibiting the conversion of carnitine to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual one or more compositions comprising a compound set forth in Formula (I): Wherein the compound is administered in an amount effective to inhibit conversion of carnitine to TMA in the individual.


Find Patent Forward Citations

Loading…